Tetris Pharma, a division of the biopharmaceutical firm Arecor Therapeutics, has entered into a service agreement with Syneos Health® to aid the expansion of Tetris’ trade capabilities throughout Europe. Syneos Health is the sole provider of entirely integrated biopharmaceutical services designed to increase consumer satisfaction.

Both companies are set to see the benefits of this collaboration, with Syneos Health offering commercial assistance in a bid to increase healthcare practitioners' knowledge of Tetris Pharma's leading diabetic treatment, Ogluo®, a glucagon prefilled autoinjector pen. The product is targeted towards individuals with diabetes in the preliminary markets.

“Tetris Pharma has entered into a service agreement with Syneos Health® to aid the expansion of Tetris’ trade capabilities throughout Europe“

MD of Tetris Pharma, Dr. Shafiq Choudhary, said that “following the recent launch of Ogluo® in Germany, we are focused on continuing its accelerated roll-out across Europe.”

“Syneos Health was one of several potential partners that were evaluated during the process of partnering with an organisation that would provide a multitude of commercial options to help establish the product across Europe.”

“Partnering with Syneos Health, a leader in clinical research, medical affairs, and commercialisation services for the pharmaceutical industry, is key to building our reputation as specialists in the marketing, sales, and distribution of commercial-stage specialty hospital products across the UK and Europe.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.